MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cesca Therapeutics Company Profile (NASDAQ:KOOL)

Consensus Ratings for Cesca Therapeutics (NASDAQ:KOOL) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $1.50 (51.30% downside)

Analysts' Ratings History for Cesca Therapeutics (NASDAQ:KOOL)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/21/2015HC WainwrightUpgradeNeutral -> Buy$2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Cesca Therapeutics (NASDAQ:KOOL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/15/2016        
2/16/2016Q216($0.07)($0.02)$4.32 million$3.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q116($0.06)($0.08)$3.71 million$2.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/17/2015Q415($0.11)($0.06)$3.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/23/2015Q315($0.08)($0.12)$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q215($0.08)($0.11)$4.08 million$4.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q115($0.08)$3.60 million$3.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/29/2014Q414($0.06)($0.09)$4.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014($0.05)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2014Q214($0.10)$4.80 million$4.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q1($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/29/2013Q4 2013($0.14)$4.50 million$4.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q113$0.06$4.90 million$4.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cesca Therapeutics (NASDAQ:KOOL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cesca Therapeutics (NASDAQ:KOOL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cesca Therapeutics (NASDAQ:KOOL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/10/2015Kenneth HarrisDirectorSell80,858$0.60$48,514.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Kenneth HarrisDirectorSell48,468$0.60$29,080.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Kenneth HarrisDirectorSell30,190$0.60$18,114.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Kenneth HarrisDirectorSell10,510$0.60$6,306.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Kenneth HarrisDirectorSell5,700$0.60$3,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Kenneth HarrisDirectorSell8,632$0.60$5,179.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Matthew T. PlavanCEOSell17,271$0.68$11,744.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cesca Therapeutics (NASDAQ:KOOL)
DateHeadline
06/21/16 09:23 AMCesca Therapeutics Appoints Mark Bagnall to Its Board of Directors - GlobeNewswire (press release)
06/20/16 05:05 AMCesca Therapeutics Appoints Mark Bagnall to Its Board of Directors - [GlobeNewswire] - RANCHO CORDOVA, Calif., June 20, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that Mr. Mark Bagnall has been appointed to the Company’ s Board ...
06/11/16 05:00 PMAnalyst's Overview of Two Stocks: XOMA Corporation (NASDAQ:XOMA) , Cesca Therapeutics Inc. (NASDAQ:KOOL) - Street Updates
06/10/16 05:05 PMTwo Buzzers within Traders Radar: Cesca Therapeutics Inc. (NASDAQ:KOOL) , ImmunoGen, Inc. (NASDAQ:IMGN) - Street Updates
06/10/16 07:44 AMCesca Therapeutics (KOOL) Clears the Hurdle - SmallCap Network
06/08/16 05:12 PMCesca Therapeutics to Exhibit at 14th International Cord Blood Symposium - GlobeNewswire (press release)
06/08/16 05:05 AMCesca Therapeutics to Exhibit at 14th International Cord Blood Symposium - [GlobeNewswire] - RANCHO CORDOVA, Calif., June 08, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 14 th International Cord ...
06/06/16 04:46 PMCesca Therapeutics to Present at the LD Micro Invitational Conference - GlobeNewswire (press release)
06/06/16 05:05 AMCesca Therapeutics to Present at the LD Micro Invitational Conference - [GlobeNewswire] - RANCHO CORDOVA, Calif., June 06, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company’ s Chief Financial Officer and ...
06/03/16 07:38 AMCesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Increased By 7.62% - HNN - Cesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Increased By 7.62%HNNWith 19,400 shares average volume, it will take short sellers 2 days to cover their KOOL's short positions. The stock decreased 2.91% or $0.09 on June 2, hitting $3. About 101,082 shares traded hands. Cesca Therapeutics Inc (NASDAQ:KOOL) has declined ...and more »
06/02/16 07:44 AMCurrent Update on Price Fluctuations: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) , Cesca Therapeutics Inc ... - Street Updates - Current Update on Price Fluctuations: Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) , Cesca Therapeutics Inc ...Street UpdatesCesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, recently declared that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its ...and more »
06/01/16 05:15 PMCesca Therapeutics (KOOL) Submits IDE Supplement for SurgWerks CLI Pivotal Trial - StreetInsider.com - Cesca Therapeutics (KOOL) Submits IDE Supplement for SurgWerks CLI Pivotal TrialStreetInsider.comCesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) ...Unusual Volume Check: Cesca Therapeutics Inc. (NASDAQ:KOOL)Franklin IndependentCesca Therapeutics Inc (NASDAQ:KOOL)'s Company Shares Increased 16.84% After Low VolatilityThe PostCesca Therapeutics Inc. (KOOL) Updated Analyst CoverageRisers & FallersBenchmark Monitorall 5 news articles »
06/01/16 10:43 AMCESCA THERAPEUTICS SUBMITS INVESTIGATIONAL DEVICE EXEMPTION SUPPLEMENT FOR SURGWERKS™ CLI PIVOTAL TRIAL - [at noodls] - Rancho Cordova, CA, June 1, 2016 - Cesca Therapeutics Inc. (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device ...
06/01/16 07:41 AMWeak On High Volume: Cesca Therapeutics (KOOL) - TheStreet.com - Weak On High Volume: Cesca Therapeutics (KOOL)TheStreet.com40.13% is the gross profit margin for CESCA THERAPEUTICS INC which we consider to be strong. Regardless of KOOL's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, ...Cesca Therapeutics Inc (NASDAQ:KOOL)'s Company Shares Increased 16.84% After Low VolatilityThe Postall 2 news articles »
05/26/16 11:21 PMCesca Therapeutics Inc. (NASDAQ: KOOL) Just Made Investors Very Happy - Scibility Media - Scibility MediaCesca Therapeutics Inc. (NASDAQ: KOOL) Just Made Investors Very HappyScibility MediaCesca Therapeutics Inc. (NASDAQ: KOOL) recently put to rest the matter over its financial flexibility. The company said it exited F3Q2016 ended March 31, 2016 with $7.2 million in cash and equivalents. According to management, the amount is adequate ...
05/26/16 06:12 PMHealthcare Top Gainers: Sarepta Therapeutics (NASDAQ:SRPT), Cesca Therapeutics Inc. (NASDAQ:KOOL), Natera ... - KC Register - Healthcare Top Gainers: Sarepta Therapeutics (NASDAQ:SRPT), Cesca Therapeutics Inc. (NASDAQ:KOOL), Natera ...KC RegisterCesca Therapeutics Inc. (NASDAQ:KOOL) announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in ...and more »
05/24/16 05:16 AMCESCA THERAPEUTICS TO EXHIBIT AT THE 2016 INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL MEETING - [at noodls] - CESCA THERAPEUTICS TO EXHIBIT AT THE 2016 INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL MEETING
05/23/16 11:09 AMHealthcare Unusual Volume: Cidara Therapeutics, Inc. (NASDAQ:CDTX), Cesca Therapeutics Inc. (NASDAQ:KOOL ... - KC Register - Healthcare Unusual Volume: Cidara Therapeutics, Inc. (NASDAQ:CDTX), Cesca Therapeutics Inc. (NASDAQ:KOOL ...KC RegisterCesca Therapeutics Inc. (NASDAQ:KOOL) announced that the Company's management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss ...
05/22/16 05:32 PMNext Weeks Broker Price Targets For Cesca Therapeutics Inc. (KOOL) - Share Trading News - Next Weeks Broker Price Targets For Cesca Therapeutics Inc. (KOOL)Share Trading NewsCesca Therapeutics Inc. has a 50 day moving average of 2.97 and a 200 day moving average of 4.78. The stock's market capitalization is 9.42M, it has a 52-week low of 1.60 and a 52-week high of 21.80. The share price of the company (KOOL) was down ...and more »
05/22/16 10:46 AMCesca Therapeutics : to Review Recent Corporate Milestones at the Marcum MicroCap Conference - (GlobeNewswire) - Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Companys management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial ...
05/21/16 12:04 PMCESCA THERAPEUTICS INC. Financials -
05/20/16 11:10 PMCesca Therapeutics Incorporated (NASDAQ:KOOL) Short Interest Decreased By 21.9% - Wall Street Hints and News - Cesca Therapeutics Incorporated (NASDAQ:KOOL) Short Interest Decreased By 21.9%Wall Street Hints and NewsWith 9,200 shares average volume, it will take short sellers 4 days to cover their KOOL's short positions. The stock increased 79.60% or $1.6 during the last trading session, hitting $3.61. Cesca Therapeutics Inc (NASDAQ:KOOL) has declined 70.41% since ...
05/20/16 06:02 PMUnusual Volume at Healthcare: Anacor Pharmaceuticals, (NASDAQ:ANAC), Cesca Therapeutics (NASDAQ:KOOL ... - KC Register - Unusual Volume at Healthcare: Anacor Pharmaceuticals, (NASDAQ:ANAC), Cesca Therapeutics (NASDAQ:KOOL ...KC RegisterOn 17 May, Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) said that, Pfizer Inc is buying Anacor Pharmaceuticals Inc in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after the U.S. drug major scrapped plans to acquire Allergan Plc ...and more »
05/20/16 01:56 PMEdited Transcript of KOOL earnings conference call or presentation 12-May-16 9:00pm GMT -
05/20/16 09:46 AMWatchful Active Movers- Achillion Pharmaceuticals (NASDAQ:ACHN), Cesca Therapeutics (NASDAQ:KOOL), Sovran ... - Seneca Globe - Watchful Active Movers- Achillion Pharmaceuticals (NASDAQ:ACHN), Cesca Therapeutics (NASDAQ:KOOL), Sovran ...Seneca GlobeCesca Therapeutics Inc. (NASDAQ:KOOL) keeps its position active in street, shares closed at $3.61 with moves up of 79.60%. Cesca Therapeutics reported publication of data from a pilot study utilizing its technology for treatment of Acute Myocardial ...and more »
05/20/16 05:00 AMCesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference - [GlobeNewswire] - RANCHO CORDOVA, Calif., May 20, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that the Company’ s management team including, Mr. Robin Stracey, ...
05/19/16 06:05 PM6 Biggest Mid-Day Gainers - Benzinga - 6 Biggest Mid-Day GainersBenzingaCseca Therapeutics Inc KOOL 104.98% up 74.12 percent after publication of data from its pilot study utilizing technology in the treatment of Acute Myocardial Infraction. Paragon Shipping Inc PRGN 40.39% up 50 percent and rebounding back towards monthly ...
05/19/16 06:05 PMCesca Therapeutics (KOOL) Surges Following Positive Pilot Study - StreetInsider.com - Money News (press release)Cesca Therapeutics (KOOL) Surges Following Positive Pilot StudyStreetInsider.comCesca Therapeutics Inc. (NASDAQ: KOOL) is surging 32% in early trade after the company announced publication of data from a pilot study utilizing the company's innovative technology for treatment of Acute Myocardial Infarction. The report was published ...Analyst Review: Cesca Therapeutics Inc. (KOOL)Risers & FallersWorth Watching Stocks: Cesca Therapeutics Inc (NASDAQ:KOOL) | Paragon Shipping Inc (NASDAQ:PRGN)Money News (press release)Cesca Therapeutics Skyrockets on Promising Data on Acute Myocardial Infarction Treatment (NASDAQ:KOOL)Sonoran Weekly ReviewWall Street Hints and News -Seeking Alphaall 9 news articles »
05/19/16 05:00 AMCesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction - [GlobeNewswire] - Data highlights promising results obtained from the AMIRST pilot study.. RANCHO CORDOVA, Calif., May 19, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced ...
05/18/16 03:42 PMCESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits -
05/18/16 12:44 PMCesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2016 By the Numbers -
05/16/16 11:10 AMCesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Decreased By 21.9% - Wall Street Hints and News - Cesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Decreased By 21.9%Wall Street Hints and NewsThe stock decreased 3.62% or $0.08 on May 13, hitting $2.13. Cesca Therapeutics Inc (NASDAQ:KOOL) has declined 82.54% since October 8, 2015 and is downtrending. It has underperformed by 84.19% the S&P500. Cesca Therapeutics Inc. is focused on ...and more »
05/13/16 08:50 AMCesca's loss more than doubles, but its regenerative treatment shows result -
05/13/16 05:09 AMCESCA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report -
05/13/16 04:45 AMCesca Therapeutics' (KOOL) CEO Robin Stracey on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha - Cesca Therapeutics' (KOOL) CEO Robin Stracey on Q3 2016 Results - Earnings Call TranscriptSeeking AlphaGood day and welcome to the Cesca Therapeutics Third Quarter Fiscal Year 2016 Financial Results Conference Call and Webcast. Please refer to the press release about this conference call on the Company's Web site, cescatherapeutics.com for further ...Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business UpdateGlobeNewswire (press release)all 3 news articles »
05/12/16 04:35 PMCESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E -
05/12/16 03:37 PMCesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update - [GlobeNewswire] - RANCHO CORDOVA, Calif., May 12, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2016 and provided ...
05/11/16 06:31 PMCesca Therapeutics (KOOL) Announces Positive Data from Late-Stage CLI Study Using SurgWerks-CLI - Claim your 2-week free trial to StreetInsider Premium here. Cesca Therapeutics Inc. (NASDAQ: KOOL) announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks-CLI system on a compassionate use basis. In a six ...
05/11/16 05:01 AM6:01 am Cesca Therapeutics announces 'favorable' outcomes in lifestyle & pain reduction in data from 6 patients treated with the SurgWerks CLI system on a compassionate use basis -
05/11/16 05:00 AMCesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks™ Procedures at Fortis Escorts Heart Institute in New Delhi - [GlobeNewswire] - RANCHO CORDOVA, Calif., May 11, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia patients treated ...
05/09/16 05:00 PMCesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016 - [GlobeNewswire] - RANCHO CORDOVA, Calif., May 09, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal third quarter ...
05/08/16 06:37 PMAfter Last Week What Do Analysts Think Of Cesca Therapeutics Inc. (KOOL) - Share Trading News - After Last Week What Do Analysts Think Of Cesca Therapeutics Inc. (KOOL)Share Trading News01/02/2015 – Cesca Therapeutics Inc. had its “buy” rating reiterated by analysts at MKM Partners. They now have a USD 7 price target on the stock. The share price of Cesca Therapeutics Inc. (KOOL) was up +0.87% during the last trading session, with a ...Cesca Therapeutics Incorporated (NASDAQ:KOOL) Shorted Shares Increased By 9.66%The Postall 2 news articles »
05/05/16 06:40 PMCesca Therapeutics Inc. (KOOL) Updated Broker Price Targets - Share Trading News - Cesca Therapeutics Inc. (KOOL) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cesca Therapeutics Inc. (KOOL). The latest reports which are currently in issue on Thursday 5th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
05/01/16 04:35 AMAre Analysts Bearish Cesca Therapeutics Inc (NASDAQ:KOOL) After Last Week? - B.O.D.Y Confidential - Are Analysts Bearish Cesca Therapeutics Inc (NASDAQ:KOOL) After Last Week?B.O.D.Y ConfidentialOut of 1 analysts covering Cesca Therapeutics (NASDAQ:KOOL), 0 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 0% are positive. Cesca Therapeutics has been the topic of 4 analyst reports since August 25, 2015 according to StockzIntelligence Inc.and more »
04/28/16 06:45 PMBroker Outlook For Cesca Therapeutics Inc. (KOOL) - Share Trading News - Broker Outlook For Cesca Therapeutics Inc. (KOOL)Share Trading NewsIt focuses in three target markets to serve patients physicians and partners: cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. The Company focuses on three areas: critical limb ...
03/16/16 05:05 AMCesca Therapeutics to Present at the ARM 4th Annual Cell & Gene Therapy Investor Day - [GlobeNewswire] - RANCHO CORDOVA, Calif., March 16, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that Mike Bruch, Cesca Therapeutics’ Chief Financial Officer, will ...
03/15/16 08:50 AMBig Chinese investor takes seat on struggling company's board -
03/10/16 02:36 PMCESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib -
03/08/16 05:11 PMMcClatchy plans move to boost share price and stay on NYSE -
03/04/16 03:05 PMCesca Therapeutics Announces 1-for-20 Reverse Split of Common Stock - [GlobeNewswire] - RANCHO CORDOVA, Calif., March 04, 2016-- Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, has amended its Certificate of Incorporation to reflect a 1- for-20 reverse stock ...
About Cesca Therapeutics

Cesca Therapeutics logoCesca Therapeutics Inc. is focused on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is engaged in developing and manufacturing automated blood and bone marrow processing systems that enable the separation processing and preservation of cell and tissue therapy products. It focuses in three target markets to serve patients physicians and partners: cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. The Company focuses on three areas: critical limb ischemia (CLI), acute myocardial infarction (AMI) and bone marrow transplant (BMT). The Company offers SurgWerks and VXP System Platform, and CellWerks Platform. Its products include AutoXpress (AXP) System, MarrowXpress (MXP) System, BioArchive System and Res-Q 60 BMC. It also provides cell manufacturing and banking services.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KOOL
  • CUSIP:
Key Metrics:
  • Previous Close: $3.08
  • 50 Day Moving Average: $2.87
  • 200 Day Moving Average: $3.65
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $9.26M
  • Current Quarter EPS Consensus Estimate: $0.46 EPS
Additional Links:
Cesca Therapeutics (NASDAQ:KOOL) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha